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Angiographic lesion characteristics can predict
adverse outcomes after carotid artery stenting
Shariq Sayeed, MD,a Stephen F. Stanziale, MD,a Mark H. Wholey, MD,b and Michel S. Makaroun, MD,a
Pittsburgh, Pa
Background: Carotid artery angioplasty and stenting (CAS) is an evolving and increasingly common endovascular
treatment for carotid artery stenosis. Risk factors associated with an increased incidence of adverse periprocedural
neurologic outcomes are being recognized. The goal of this study was to determine if certain angiographic lesion
characteristics were predictive of higher risks of adverse outcomes.
Methods: A total of 421 patients who underwent 429 carotid artery stenting procedures between June 1996 and June 2005
for symptomatic or asymptomatic carotid stenosis, and in whom preoperative carotid angiograms and follow-up records
were available for review, were selected from a prospectively maintained database. Demographic data and procedural
variables were recorded, including the presence or absence of the use of a cerebral protection device. Angiograms were
reviewed for the following carotid lesion characteristics: length of lesion, percentage of stenosis, ostial involvement, lesion
ulceration, calcification, and presence of contralateral carotid occlusion. Periprocedural stroke and 30-day adverse event
rates (stroke, myocardial infarction, and death) were recorded for each patient.
Results: The periprocedural all-stroke rate was 3.7%. Octogenarians had a higher incidence of 30-day adverse events at
10.0% vs 3.8% (P  .029). The incidence of periprocedural stroke was increased in lesions >15 mm long, at 17.0% (8 of
47) vs 2.1% (8 of 382; P < .001), and in ostial centered lesions, 7.1% (11 of 154) vs 1.8% (5 of 275; P  .007).
Multivariate regression also identified these two variables as independently associated with 30-day stroke rate: lesion
length >15 mm (odds ratio [OR], 6.38; 95% confidence interval [CI], 35 to 17.29) or ostial involvement (OR, 3.12; 95%
CI, 3.12 to 8.36). Other variables, including lesion calcification, ulceration, degree of stenosis, or presence of
contralateral occlusion, were not associated with adverse outcomes. When studied separately, the use of cerebral
protection devices in 241 patients (56%) did not change our observed correlations between angiographic characteristics
and adverse procedural events.
Conclusions: Certain lesion characteristics on angiography, such as length and ostial location, can predict adverse
outcomes. The indication for CAS should be carefully evaluated in these cases. ( J Vasc Surg 2008;47:81-7.)An abundance of evidence shows the benefit of reliev-
ing high-grade symptomatic and asymptomatic carotid ar-
tery stenosis by carotid endarterectomy (CEA).1-5 More
recently, carotid angioplasty and stenting (CAS) has been
presented as an alternative to CEA for the treatment of
carotid artery stenosis.6-13 Both can be associated with
complications, most notably, temporary or permanent neu-
rologic deficits. Most of these events are related to throm-
bosis, distal embolization, or hemodynamic compromise.
Factors associated with a higher incidence of complications
for both procedures are progressively being described.
High-risk categories for CEA have gained widespread
recognition, but only recently has attention focused on the
identification of patients who are at greater risk for adverse
outcomes during and after CAS. Only one clear limitation
has become evident so far, namely, the higher rate of
adverse outcomes in patients 80 years old. The Carotid
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(CREST) lead-in phase and other studies have shown in-
creased rates for stroke and stroke and death in octogenar-
ians.14,15 The increase in adverse outcomes seen with this
population may be at least partly related to anatomic factors
such as adverse arch anatomy and vessel tortuosity.16 Other
anatomic and patient characteristics may be associated with
adverse outcomes but have not yet been fully described.
The composition of the target lesion has been found to
be a predictor of stroke after CAS.17 Less is known, how-
ever, about the anatomic characteristics and their associa-
tion with outcomes. The goal of this study was to evaluate
our database of CAS patients to determine if certain angio-
graphic lesion characteristics were predictive of higher risks
of adverse outcomes. This will help standardize the charac-
terization of patients considered for CAS and help plan
strategies to reduce complications.
METHODS
This study was approved by the Institutional Review
Board of the University of Pittsburgh.
Patient population. From June 1996 to June 2005,
950 patients underwent CAS at ShadysideHospital of the
University of Pittsburgh Medical Center. Neurologists
evaluated the patients before and24 hours after the CAS
procedure. A total of 429 CAS procedures met the mini-
mum requirements for the review, which included (1)
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ent views of the carotid lesion, and (2) available follow-up
records that included a preprocedural, an intraprocedural,
an immediate postprocedural evaluation, and a 30-day
follow-up visit.
Carotid artery stent procedure. Patients underwent
CAS in the angiography suite by one of three intervention-
alists. All procedures were performed under local anesthesia
with intravenous sedation. Aortic arch and cerebral angiog-
raphy was performed before the stenting procedure. Dur-
ing the first year of patient accrual, patients were treated
preprocedurally with ticlopidine (250 mg, twice daily). In
the ensuing years of the study, patients received a 300-mg
loading dose of clopidogrel and a maintenance dose of 75
mg daily for a minimum of 3 months. Aspirin was initiated
only if indicated in the regulatory trial in which the patient
was enrolled or by discretion of the interventionalist. No
changes were made to a patient’s regimen if he or she was
already taking aspirin. During stenting, patients received
anticoagulation with heparin to a target activated clotting
time of 275 seconds.
Several stent systems were used, depending on the
regulatory trial in which patients were enrolled, and in-
cluded Precise in 80 (Cordis Endovascular, Miami Lakes,
Fla), Smart in 106 (Cordis Endovascular), NextStent in 46
(EndoTex Interventional Systems, Cupertino, Calif), Ac-
culink in 160 (Abbott Vascular, Santa Clara, Calif), and
Wallstent in 32 (Boston Scientific, Natick, Mass). Embolic
protection devices were coupled with the stents as systems
according to regulatory trial protocols and included Angio-
guard (Cordis Endovascular), Accunet (Abbott Vascular),
PercuSurge (Medtronic, Minneapolis, Minn), and Epi Fil-
terWire (Boston Scientific). The use of cerebral protection
became standard by July 2000. In patients not participating
in a trial, stents and protection devices were inserted at the
discretion of the interventionalist. The study excluded
three patients who received balloon expandable stents.
Definitions. Stroke or cerebrovascular accident
(CVA) was defined as a neurologic deficit lasting at least 24
hours. No distinction was made between minor and major
strokes, and all ipsilateral and contralateral strokes were
included. Transient ischemic attack (TIA) was defined as
focal retinal or cerebral event from which there was no
neurologic sequelae after 24 hours. Death was qualified as
either a direct sequelae of stroke or from another cause.
Evaluation of angiograms. Digital subtraction an-
giographic images were collected retrospectively from the
digital tape storage system of our angiography unit (Gen-
eral Electric, Milwaukee, Wis), from hard-copy angiogra-
phy films, or from our digital radiologic archive (Stentor/
Philips Medical Systems, Foster City, Calif). Ipsilateral and
contralateral diagnostic images of the extracranial carotid
arteries and the intracranial circulation were obtained be-
fore carotid stent placement. Images of the stented artery
and of the intracranial circulation were also obtained after
stent placement. The digital images of the extracranial
carotid arteries were evaluated on a digital workstation with
digital calipers. Hard-copy films of digital subtraction im-ages were evaluated with a hand-held digital caliper (Abso-
lute Digimatic, Mitutoyo USA, Aurora Ill). One investiga-
tor (S. S.) performed all of the measurements and was
blinded to patient clinical information and outcomes. All
measurements were digitally standardized to the known
diameter of a guiding sheath or other standard internal
control.
Angiographic lesion characteristics were recorded and
defined as follows:
● Lesion length was defined in accordance with the Amer-
ican Heart Association/American College of Cardiol-
ogy classification as modified by Ellis, et al.18 Briefly,
defined as the distance from the definite proximal to
distal shoulder of the lesion in the projection that best
elongated the stenosis. Only the portion of stenosis
that was  50% was quantified.
● Stenosis diameter was determined by the North Amer-
ican Symptomatic Carotid Endarterectomy Trial
(NASCET) criteria, with the distal internal carotid
serving as the reference segment. The most severe
stenosis from a minimum of two projections was re-
ported.
● Ostial involvement was indicated by a stenosis that was
ostially centered; that is, the maximal point of stenosis
was located at the internal carotid ostium.
● Ulceration of the plaque was noted if the plaque ful-
filled radiographic criteria of ulcer niche, seen in profile
as a crater from the lumen into a stenotic plaque and
(when visible) a double density on face view.19,20
● Calcification was defined as radiologic densities readily
seen within the apparent vascular wall of the artery at
the site of the stenosis.18
● Contralateral carotid occlusion was defined as 100%
occlusion of the contralateral common carotid or in-
ternal carotid arteries.
Data collection. Clinical, demographic, and stenting
data were prospectively recorded on standard forms and
entered into a database. Clinical and demographic data
included age, sex, presence of symptoms in the last 60 days,
and prior CEA. All periprocedural (24 hours) events were
recorded. Primary clinical end points included stroke,
death, or myocardial infarction 30 days of procedure.
Patients were considered symptomatic if they had TIAs,
amaurosis fugax, or stroke with clinically correlated, later-
alizing symptoms60 days preceding the carotid interven-
tion. Outside of this window, patients were considered
asymptomatic.
Morphologic data were recorded retrospectively by
reviewing angiographic films. The morphologic variables
studied were lesion length, ostial involvement, calcification,
plaque ulceration, and lesion severity. The presence of
contralateral carotid artery occlusion was also recorded.
Procedural variables were recorded and included the pres-
ence or absence of the use of a cerebral protection device.
Statistical analysis. Periprocedural and 30-day ad-
verse event rates by demographic, angiographic, and device
characteristics were summarized as percentages. Statistical
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Fisher exact test. The Cochran-Mantel-Haenszel statistic
was used to evaluate trends in adverse event rates and lesion
length categories. Logistic regression was used to deter-
mine variables associated with 30-day stroke, and the risk is
represented by the odds ratio (OR). Logistic regression was
used to initially screen all clinical variables for univariate
association with 30-day outcomes of interest at P  .15.
Individual variables identified were then assessed in a for-
ward stepwise manner using a criterion of P  .05. The final
model included all significant variables and any other vari-
ables thought to be relevant (eg, age). Goodness-of-fit was
assessed using the Hosmer-Lemeshow method, and all
models were considered to be adequate (P  .05).
RESULTS
Demographic, clinical, and morphologic char-
acteristics. A total of 429 carotid arteries in the 421
patients were treated during 429 procedures. In five of the
429 procedures (1.2%), carotid stenting was aborted before
stent insertion secondary to various technical complexities,
and no procedural or postprocedural morbidity developed
in these patients. A recorded evaluation by a neurologist
was available in 96% of patients. The mean age of the
patients was 72.3  8.7 years: 144 (34.2%) were 70, 188
patients (44.7%) were 70 to 79, and 89 (21.1%) were 80.
Men comprised 61.5% of the study population.
Univariate analysis was used to evaluate patient charac-
teristics and comorbidities, including gender, coronary ar-
tery disease, congestive heart failure, hypertension, diabetes
mellitus, prior myocardial infarction, chronic obstructive
pulmonary disease, smoking, and hypercholesterolemia for
association with 30-day major adverse events of stroke,
myocardial infarction, and death. No relationship was
found, and these results have previously been published.15
Asymptomatic carotid artery stenosis was present in 65% of
patients. Prior ipsilateral CEAs were present in 134 patients
(32.1%). Cerebral protection devices were used in 241of
the total procedures (56.2%).
Procedural outcomes. A periprocedural stroke oc-
curred in 16 patients (3.7%), of which 15 were ipsilateral
and one was contralateral. An ipsilateral stroke developed in
an additional three patients after the periprocedural period
but 30 days (days 1, 14, and 23); as a result, the 30-day
stroke rate for this study was 4.4%. Myocardial infarction
occurred periprocedurally in one patient (0.2%) and 30
days in another patient. Two patients (0.47%) died peripro-
cedurally, and an additional six patients died 30 days.
Seven of these eight patients (88%) had a periprocedural
stroke and died from hemorrhagic conversion of their
infarct (n  2) or from other sequelae of their periproce-
dural infarct; thus, most deaths were stroke related.
The overall periprocedural adverse event (stroke,
death, or myocardial infarction) rate was 3.96%, and the
30-day adverse event rate was 5.1% (Table I). The differ-
ence in the 30-day stroke rate between asymptomatic
(3.9%) and symptomatic patients (5.3%) was not significant
(P  .623).Octogenarians had more adverse events than younger
patients (Table II). The incidence of perioperative stroke
was 2.6% in patients 80 years and 7.8% in those 80 (P 
.053). The incidence of 30-day death also paralleled this
difference: 0.9% for younger patients and 5.6% for octoge-
narians (P  .012). When grouping major adverse events
(stroke, death, or myocardial infarction), the incidence was
3.8% in younger patients and 10.0% in octogenarians (P 
.029).
Cerebral protection was used in 241of the 429 proce-
dures (56.2%). The incidence of perioperative stroke in
patients without cerebral protection was 4.8% vs 2.9% in
those who had CAS with a cerebral protection device (P 
.32). The incidence of 30-day stroke was also similar at
5.8% vs 3.3 (P  .24). Five different stent systems were
used during this study, and there were no differences in
outcomes depending on system type.
Morphologic characteristics and postprocedural
events. Angiographic lesion characteristics and associated
outcomes are summarized in Table II. Lesion calcification,
ulceration, and degree of stenosis were not significantly
associated with neurologic complications. The presence of
contralateral occlusion was also not significantly associated
with periprocedural adverse events.
The median SD length of carotid lesions was 8.23
5.2 mm (range, 1.00 to 31.05 mm): 95 lesions (22.1%)
were 5.0 mm, 182 (42.4%) were 5 to 10 mm, 105
(24.5%) were 10 to 15mm, and 47 (11.0 %) were15mm.
Lesions 15 mm were associated with higher risk of ad-
verse outcomes. The incidence of periprocedural stroke was
2.1% in patients treated with lesions 15 mm compared
with 17.0% in patients with a treated lesion 15 mm (P 
.001). Patients with treated long lesions were also more
likely to experience 30-day adverse events: 15 mm, 3.4%
vs 15 mm, 19.1% (P  .001).
No trend in the risk of adverse events was noted in
patients with treated lesions15 mm (P trend.80 for all
comparisons). The incidence of periprocedural stroke in
patients with lesions 5.0 mm, 5 to 10 mm, and 10 to 15
mm was, respectively, 2.1%, 2.2%, and 1.9% (overall P
.99), and the respective incidence of adverse events 30
days was 3.2%, 3.3%, and 3.8% (overall P  .96).
Lesions in which the maximal point of stenosis was
located at the internal carotid ostia were seen angiographi-
cally in 154 of the vessels (35.9%) that were studied. The
Table I. Procedural outcomes
Outcome
Periprocedural
(%)
30-day
(%)
Stroke 3.7 4.4
Transient ischemic attack 3.0 3.3
MI 0.23 0.47
Death 0.47 1.9
Adverse event (stroke, death, MI) 3.96 5.1
MI, Myocardial infarction.incidence of periprocedural stroke was 7.1% in patients with
JOURNAL OF VASCULAR SURGERY
January 200884 Sayeed et altreated lesions with ostial centering vs 1.8% in patients with
treated lesions without ostial centering (P .007). Rates of
30-day adverse events were also greater in patients with
ostial lesions (9.1% vs 2.9%; P  .01).
Multivariable logistic regression identified three main
effects as being associated with 30-day stroke (Table III):
age 80, ostial lesions, and lesion length 15 mm. The
strongest predictor was lesion length 15 mm (OR, 6.38;
95% CI, 2.35 to 17.29), followed by the treatment of a
lesion in the ostium (OR, 3.12; 95% CI, 3.12 to 8.36). Age
also was associated with a higher risk of stroke; however,
statistical significance was not met at the P .05 level (OR,
2.49; 95% CI, 0.93 to 6.67; P  .069).
To evaluate the interactions between octogenarian sta-
tus and ostial involvement or lesion length, multivariate
analysis was performed to evaluate for a confounding effect
(Table IV). In this analysis, the comparison group is pa-
tients 80 years old with a lesion 15 mm. Even though
Table II. Correlation of clinical and angiographic features
Variable Patients, No.
Periprocedural
stroke (%)
Age  80
No 339 2.6
Yes 90 7.8
Ulceration
No 286 4.2
Yes 143 2.8
Calcification
No 185 3.2
Yes 244 4.1
Ostial centered
No 275 1.8
Yes 154 7.1
Lesion length 15 mm
No 382 2.1
Yes 47 17
Stenosis, %
59 76 1.3
60-69 102 5.9
70-79 120 2.5
80-89 81 4.9
90 50 4
Contralateral occlusion
No 371 4
Yes 58 1.7
Cerebral protection
No 188 4.8
Yes 241 2.9
Table III. Independent risk factors associated with 30-
day stroke using logistic regression
Factor OR 95% CI P
Age 80 2.49 0.93-6.67 .069
Ostial-centered lesion 3.12 1.17-8.36 .023
Lesion 15 mm 6.38 2.35-17.29 .001
OR, Odds ratio; CI, confidence interval.the greatest risk of stroke was in the subgroup of patientswho were80 years andwho had long lesions (OR, 13.12;
95%CI, 2.81 to 61.31), a long lesion was also a predictor of
stroke amongst nonoctogenarians (OR, 8.77; 95%CI, 2.47
to 31.10). Ostial-centered lesions also were a significant
risk factor independent of octogenarian status.
The routine of use of cerebral protection devices started
in July 2000 for this study group, and thus the devices were
used in 241 of the 429 procedures. To study if the routine
use of a cerebral protection device had any impact on the
correlation between angiographic characteristics and pro-
cedural events during CAS, this subpopulation was studied
separately (Table V). Lesions 15 mm were associated with
increased risk of 30-day stroke vs lesions 15 mm (16.7%
postprocedural events
30-day stroke (%) P
30-day adverse
event (%) P
.037 .029
3.2 3.8
8.9 10
.62 .82
4.9 4.9
3.5 5.6
.35 .18
3.2 3.2
5.3 6.6
7 .015 .01
2.5 2.9
7.8 9.1
1 .002 .001
2.9 3.4
17 19.1
.75 .5
3.9 5.3
6.9 7.8
2.5 2.5
4.9 6.2
4 4
.49 .34
4.8 5.7
1.7 1.7
.24 .076
5.8 7.4
3.3 3.3
Table IV. Interaction between age and lesion length or
ostial involvement associated with 30-day stroke using
logistic regression
Variable OR 95% CI P
Age and lesion length vs 80 y
and 15 mm
Age 80 y and lesion 15
mm
3.36 0.99-11.42 .052
Age 80 y and lesion 15
mm
8.77 2.47-31.10 .001
Age 80 y and lesion 15
mm
13.12 2.81-61.31 .001
Ostial-centered lesion 3.09 1.16-8.25 .024with
P
.53
.59
.8
.00
.00
.72
.71
.32vs 1.84%, P  .004). Increases in 30-day stroke rates were
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(0.7%) involvement (P  .01). Logistic regression showed
ostial involvement and a lesion 15 mm were strong
predictors of adverse outcome, even in the subgroup of
patients who received cerebral protection during CAS (Ta-
ble VI).
DISCUSSION
The quickly evolving technique of CAS, which is an
alluring and minimally invasive alternative to CEA, is being
analyzed in a number of centers around the world. The
primary objective of this study was to identify morphologic
lesion characteristics that may affect the procedural risk of
CAS. Although advanced age was a significant predictor of
complications in our study, some anatomic lesion charac-
teristics were independent predictors of adverse neurologic
event rates.
We identified two angiographic lesion risk factors sig-
nificantly associated with periprocedural neurologic deficits
and adverse outcomes: the presence of long stenotic lesions
(15 mm) and involvement of the internal carotid ostium.
Our median lesion length was 8.2 mm, yet a number of the
patients in our study population had long lesions that were
Table V. Correlation of angiographic features with
postprocedural events in patients with cerebral protection
Feature 30-day adverse event (%) P
Ulceration .71
No 3
Yes 4
Calcification 1
No 3.1
Yes 3.5
Ostial centered .01
No 0.7
Yes 6.9
Length 15 mm .004
No 1.8
Yes 16.7
Stenosis, % .28
59 5.9
60-69 2.4
70-79 0
80-89 4.9
90 4.8
Contralateral occlusion 1
No 3.6
Yes 2.1
Table VI. Independent risk factors associated with 30-
day adverse event using logistic regression in patients with
cerebral protection
Factor OR 95% CI P
Ostial-centered Lesion 9.38 1.10-80.29 .041
Lesion 15 mm 9.66 2.11-44.32 .003
OR, Odds ratio; CI, confidence interval.15 mm. These individuals had an alarming rate ofperiprocedural stroke (17.0%) and 30-day adverse events
(19.1%).
No comments can be made about the composition of
these long plaques and whether they inherently differ from
shorter lesions. Longer lesions, however, have a larger
atherosclerotic “plaque burden” and hence conceivably
carry a higher risk that particles will be dislodged during
balloon angioplasty and stenting. Longer lesions also may
require longer stents and, at times, multiple angioplasties to
ensure adequate stent dilation across a stenosis.
Highly stenotic lesions were not associated with in-
creases in stroke rates or adverse outcomes. Lesions with
90% stenosis had similar adverse neurologic events as
lesions that were less stenotic. One would contemplate that
maneuvering beyond a tight stenosis would be more pre-
carious than maneuvering through a stenosis of lesser de-
gree and would thus be associated with a greater number of
unfavorable neurologic events; however, our finding was
consistent with findings in other studies.21,22 It is possible
that lesion length is a better predictor of adverse outcome
with CAS than the percentage of stenosis simply because it
correlates better with a plaque’s “exposed surface area” and
hence more plaque burden.
Lesions in which the maximal point of stenosis was
located at the internal carotid ostium were also associated
with an increase in periprocedural stroke of 7.1% vs 1.8%.
Some of these lesions, despite having a point of maximal
stenosis elsewhere in the internal carotid artery, would
“extend” to the ostium. We, however, limited the defini-
tion of ostial involvement to include only lesions that had
their maximal stenosis at the internal carotid artery ostia.
The reason for the observed increased risk with ostial
lesionsmay bemultifactorial. It is possible that ostial lesions
simply are more difficult to initially engage with a wire
compared with more distal lesions, and as a result have an
increased risk of triggering embolic debris. Another mech-
anism may be hemodynamic instability (hypotension, bra-
dycardia, transient asystole, or a combination) associated
with carotid sinus stimulation, which has been shown to
occur more often in patients with ostial lesions.23 Such
instability has been associated with stroke and cardiac com-
plications.24-26 Hence, it is plausible that our observed
increase in neurologic events observed with ostial lesions
during CAS may be related to more hemodynamic hyper-
reactivity during the procedure. Unfortunately, such de-
tailed events were not recorded prospectively to allow
further testing.
One limitation of our study was the long accrual span,
during which many technical advances in CAS occurred,
including the development of cerebral protection. Even
though our patients who underwent CAS with cerebral
protection did have lower rates of neurologic adverse
events, these rates were not significant. This inability to
demonstrate a significant difference may be due to small
sample size (type II error).
Also of note, when our subgroup of patients who
underwent CAS with cerebral protection was analyzed,
those with ostial and long lesions continued to show sig-
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associated with increases in intervention time and may have
a negative influence on embolization rates themselves.27,28
It is possible that the maneuvering of filter devices through
ostial or long lesions before their deployment may be a
significant cause for the observed events associated with
these lesions.
A second shortcoming was the exclusion of a large
number of patients (n  521) who lacked complete 30-day
follow-up (n  413) or the unavailability of complete
angiographic films (n  108). The sample size however
remains high enough to allow the comparisons to be valid.
Although not well characterized, other anatomic char-
acteristics may affect the incidence of adverse neurologic
events after CAS, such as atherosclerotic arch disease, tor-
tuosity, or origin of the great vessels.29,30 These were not
included in our analysis and may have eliminated some
potential confounding variables. Unfortunately, many of
these were not always accessible and would have eliminated
many subjects from analysis. It is unlikely, however, that
these variables would have changed our results signifi-
cantly, because lesion length and ostial location have never
been related to arch abnormalities.
The low incidence of event rates after CAS may have
prevented the identification of other predictive factors of
adverse outcomes. Evidence is mounting, however, that
subclinical infarction may be much more common with
CAS than previously suspected. A prospective analysis in-
cluding diffusion-weighted magnetic resonance imaging
may provide better correlation of adverse outcomes of CAS
with lesion characteristics.31,32 All events analyzed in our
report were noted on clinical examination, which may
underestimate the true incidence of embolization and the
effect of certain anatomic characteristics. Because clinical
events after CAS are fairly infrequent, additional surrogate
markers for clinical stroke and silent cerebral ischemia that
occur at greater frequencies would be of use.
Other lesion characteristics not identified on angiogra-
phy, such as gray-scale median (GSM), may be as important
as those identified in this study. Biasi et al17 have found that
a GSM 25, associated with echolucent plaques, predicts
accurately a high incidence of neurologic events after
CAS.17 Characterizing lesions with virtual histology-
assisted intravascular ultrasound imaging may also help to
determine the compositions of ostial and long lesions and if
they inherently differ from other lesions.
Our study suggests that a combination of risk factors
may be additive in predicting complications. Once all fac-
tors such as arch anatomy, lesion characteristics, and phys-
iologic factors such as age and symptoms are ultimately well
defined, a high-risk patient category for CAS is likely to
emerge that will permit better selection of cases. It would
be interesting to evaluate other large existing CAS data-
bases (Society for Vascular Surgery Registry and various
European databases) for additional confirmation of our
results. This is likely to identify contraindications for CAS
and categories of patients with expected good outcomes.CONCLUSION
It is evident that certain lesion characteristics on an-
giography, such as length and ostial location, can predict
outcomes after CAS. Until further validation of these find-
ings, caution and restraint should be exercised in stenting
these lesions.
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